Preliminary Program
Preliminary Program: Thursday May 23
Psychiatric News
Volume 37 Number 4 page 54-68
Anchor for JumpAnchor for Jump

This beautiful stairway is one of the Pennsylvania Convention Center's design elements that help create a pleasant atmosphere for meeting goers. Its light-filled, colorful spaces prevent the cavelike feel common to other convention centers. (Photo: Top Kat)

7 a.m.-8:30 a.m.

Industry-Supported Breakfast Symposia

IS38. Chronic Episodic Disorders: Comorbidity and Comprehensive Integrated Treatment (Part 2) Supported by GlaxoSmithKline

A. New Developments in Obesity Donna H. Ryan, M.D.

B. Comorbid Physical Symptoms Associated With Female-Specific Mood Disorders Julia K. Warnock, M.D.

IS39. Age, Gender, and Diagnosis: Influences on Drug Response (Part 2) Supported by Pfizer Inc.

A. Can Treating Depression Alter Cardiovascular Disease? Alexander H. Glassman, M.D.

B. Comorbidity and Its Implication for Treatment: Change Over the Life Span Tana A. Grady-Weliky, M.D.

IS40. Therapeutic Challenges, Novel Approaches: Antipsychotics in the Management of Mood and Anxiety Disorders (Part 2) Supported by Eli Lilly and Company

A. Psychotic Features in Illness Severity in Combat Veterans With Chronic PTSD Frederick Petty, M.D.

B. Interplay Between Disease and Treatment Regimen: Special Safety Considerations Olga Brawman-Mintzer, M.D.

IS41. The Pathophysiology and Treatment of Impulsivity and Aggression in Psychiatric Disorders (Part 2) Supported by Abbott Laboratories

A. Violence, Substance Use Disorders, and PTSD Kathleen T. Brady, M.D.

B. The Role of Impulsivity in Bipolar Disorder Daniel E. Casey, M.D.

IS42. New Perspectives on Schizophrenia Spectrum Disorders and Their Treatment (Part 2) Supported by Janssen Pharmaceutica

A. The Schizophrenia Prodrome: Early Treatment Findings Barbara Cornblatt, Ph.D.

B. Validating Schizotaxia Criteria for Future Prevention of Schizophrenia Ming T. Tsuang, M.D.

7:30 a.m.-2 p.m.

Registration/Course Enrollment Opens

8 a.m.-Noon

CME Courses 97-99

9 a.m.-10:30 a.m.


L24. Does the Psychiatric Hospital Have a Future? Steven S. Sharfstein, M.D.,APA’s Administrative Psychiatry Award Lecture

Component Workshops

CW50. Career Choices in Psychiatry APA Assembly Committee of Area Member-in-Training Representatives Co-Chairpersons: Shauna P. Reinblatt, M.D., Pamela J. Petersen-Crair, M.D.

CW51. Coding and Documentation Update APA Committee on RBRVS, Codes, and Reimbursements Co-Chairpersons: Chester W. Schmidt Jr., M.D., Tracy R. Gordy, M.D.

CW52. Psychological Issues of People Living Longer With HIV APA Commission on AIDS Chairperson: Warren M. Liang, M.D.

CW53. Information Technology: Core Competencies for Psychiatrists APA Committee on Information Technology Chairperson: Ronnie S. Stangler, M.D.

CW54. Surgeon General’s Report on Culture, Race, and Ethnicity: Clinical Implications APA Council on National Affairs Co-Chairpersons: Sylvia W. Olarte, M.D., Theresa M. Miskimen, M.D.

CW55. Bad Boys, Bad Girls: The Demonization of Adolescence APA Committee on Juvenile Justice Issues Chairperson: Louis J. Kraus, M.D.

Issue Workshops

IW96. Stigma Stayed: The Cost of Prejudice in High Places Chairperson: Karl S. Burgoyne, M.D.

IW97. The Other Side of the Mountain: From Residency to Reality Chairperson: Stephen M. Goldfinger, M.D.

IW98. Toward Global Decriminalization of Drug Addiction Co-Chairpersons: Rodrigo A. Muñoz, M.D., Guido Belsasso, M.D.

IW99. Poems on Psychiatry Chairperson: Charles R. Joy, M.D.

IW100. How to Give a More Effective Lecture: Punch, Passion, and Polish Chairperson: Phillip J. Resnick, M.D.

IW101. Teaching Primary Care Residents About Depression and Suicide: Can Technology Alter Outcomes? Chairperson: Donna M. Sudak, M.D.

IW102. Religious and Spiritual Assessment in Clinical Practice Chairperson: Francis G. Lu, M.D.

IW103. Lithium Revisited: Integrating Recent Findings Into Clinical Practice Co-Chairpersons: Robert T. Dunn, M.D., Eric G. Smith, M.D.

IW104. The Disruptive Physician and Hospital Culture Co-Chairpersons: Glenn N. Siegel, M.D., Mary Pittman, M.S.

IW105. Evidence-Based Tables of Side Effects of Psychotropic Medications: Useful? Co-Chairpersons: David N. Osser, M.D., Andrew A. Sassani, M.D.

IW106. Using Your Psychiatric Skills to Build a Productive Team at Work Chairperson: Saul M. Levin, M.D.

IW107. The Frontier of Public Health Psychiatry: Preventing Suicide Substance Abuse and Mental Health Services Administration Chairperson: Eric D. Caine, M.D.

IW108. Medication Use for Children in Systems of Care Substance Abuse and Mental Health Services Administration Co-Chairpersons: Gary De Carolis, M.Ed., David Fassler, M.D.

IW109. Working Through in Psychotherapy Chairperson: Steven H. Lipsius, M.D.

IW110. Alpha-Down EEG Biofeedback: A Novel Treatment for Anxiety Chairperson: Thomas M. Brod, M.D.

IW111. Joining Forces: Working With Law Enforcement to Serve the Mentally Ill Chairperson: Debra A. Pinals, M.D.

IW112. Erik Erikson Epigenesis as Depicted in Andrew Lloyd Webber’s Musicals Co-Chairpersons: Hani Raoul Khouzam, M.D., Robert W. Hierholzer, M.D.

9 a.m.-Noon

Continuous Clinical Case Conference

Richard G. Hersh, M.D., and Mary S. Sciutto, M.D., on Managing Negative Outcomes in General Psychiatry: Part II (Open to APA members only.)

9 a.m.-4 p.m.

CME Courses 100-102

11 a.m.-12:30 p.m.

Medical Update 4. Marla J. Gold, M.D., on Comprehensive HIV Care: Treatment and Service Update

Research Consultation 3. Elizabeth B. Weller, M.D., on Bipolar Disorders in Children and Adolescents

Scientific and Clinical Report Sessions

Session 34. Forensic Psychiatry

99. Medications, Strange Intoxications, and Violent Crime Michael M. Welner, M.D.

100. Treating Mentally Ill Offenders in a Residential Treatment Unit Cristinel M. Coconcea, M.D.

101. Presidential Assassination Syndrome Revisited: New Understanding David A. Rothstein, M.D.

Session 35. Issues in Trauma and Violence

102. Predicting Chronicity in Vietnam Veterans With PTSD: New Findings From the National Vietnam Veterans Readjustment Study Randall D. Marshall, M.D.

103. Community and Inpatient Violence in Major Psychiatric Disorders Menahem I. Krakowski, M.D.

104. Parental Separation at Birth and Criminality in Adulthood Pirjo H. Maki, M.D.

Session 36. Uses of Antipsychotics

105. Polypharmacy in Patients With Schizophrenia Robert E. McCue, M.D.

106. The Use of Atypical Antipsychotics in Adults With Developmental Disability Karen J. Shedlack, M.D.

Session 37. Mood Disorders in Children

107. Anxiety Disorders in Children and Adolescents With Bipolar Disorder Giulio Perugi, M.D.

108. Comorbidity in Child and Adolescent Major Depression Atilla Turgay, M.D.

109. Evaluation and Intervention of Prodromal Symptoms of Bipolar I Disorder Mohammad Z. Hussain , M.D.

Session 38. Issues in Depression

110. Dysthymic Disorder: Integrating Research Findings Into Clinical Treatment David J. Hellerstein, M.D.

111. Effect of Adjunct Modafinil on Energy and Concentration in Depressed Patients Matthew A. Menza, M.D.

112. Parental Separation at Birth and Depression in Adulthood Juha M. Veijola, M.D.

Session 39. Clinical Approaches in Schizophrenia

113. Low-Frequency Transcranial Magnetic Stimulation Curtails Medication-Resistant Auditory Hallucinations Ralph E. Hoffman, M.D.

114. Sibutramine Treatment of Obesity in Schizophrenia Ljiljana Radulovic, M.D.

115. The Stabilization Phase of Schizophrenia: A Review of the Literature Peter J. Weiden, M.D.

Session 40. Managed Care and Health Care Findings

116. Alzheimer’s Disease Increases Costs of Comorbidities in Medicare Managed Care Howard Fillit, M.D.

117. Donepezil Is Associated With Lower Health Care Costs in Medicare Managed Care Jerrold W. Hill, Ph.D.

118. Managed Care and Malpractice Liability: Update 2002 Eugene L. Lowenkopf, M.D.

Session 41. Treatment Techniques

119. Matching Treatment to Type of Poor-Prognostic, Substance-Dependent Patients Edward Gottheil, M.D.

120. Tiagabine, a Selective GABA Reuptake Inhibitor for the Treatment of Anxiety Daniel L. Crane, M.D.

121. Adjunctive Use of Tiagabine With Antidepressants in PTSD Michael E. Lara, M.D.

Session 42. Trends in Suicide Rates

122. Female Suicides in Texas Cities: 1994-1998 Veena R. Doddakashi, M.D.

123. Trends in Suicide Rates in New York City: Implications for a Prevention Initiative Neal L. Cohen, M.D.

124. Changing Suicide Rates in Europe: Possible Causes Zoltan Rihmer, M.D.

Component Workshops

CW56. Guidelines for the Treatment of Suicidal Behaviors APA Steering Committee on Practice Guidelines Chairperson: John S. McIntyre, M.D.

CW57. Asian Americans in Intermarriages: Psychosocial Adjustment and Identity APA Caucus of Asian-American Psychiatrists Chairperson: Jagannathan Srinivasaraghavan, M.D.

Issue Workshops

IW113. Bridges for Healing: Integrating Family Therapy and Psychopharmacology Chairperson: Roy O. Resnikoff, M.D.

IW114. Video Case Studies of Couples in Treatment Chairperson: Ian E. Alger, M.D.

IW115. Outpatient Commitment: Kendra’s Law and the New York City Experience Co-Chairpersons: David A. Trachtenberg, M.D., and Michael S. Lesser, M.D.

IW116. Creating Effective Alliances With Pharmaceutical Industry Physicians Chairperson: Arthur L. Lazarus, M.D.

IW117. Substance Abuse Prevention and Treatment: A Psychiatric Perspective Substance Abuse and Mental Health Services Administration Chairperson: Sheila Harmison, D.S.W.

IW118. How to Develop a Lecture Co-Chairpersons: Marianne T. Guschwan, M.D., Susan Tapert, Ph.D.

IW119. A Clinician’s Guide to Substance Abuse Treatment for Gay, Lesbian, Bisexual, and Transgender Persons Substance Abuse and Mental Health Services Administration Chairperson: Saul M. Levin, M.D.

Noon-1:30 p.m.


12. PSYOP: Psychological Operations in the War Against Terrorism Chairperson: Ronnie S. Stangler, M.D.

13. The Pharmaceutical Industry and APA: Controversies and Approaches APA Committee on Commercial Support Chairperson: Stephen M. Goldfinger, M.D.

Noon-2 p.m.

New Research Poster Session 10

2 p.m.-5 p.m.


S76. Culturally Competent Mental Health Care: Identifying and Reducing Disparities

A. Bipolar Disorder in African Americans William B. Lawson, M.D.

B. Mental Health Care in Hispanic Populations: Clinical and Therapeutic Issues Renato D. Alarçon, M.D.

C. Cultural Competence Standards for Mental Health Services Francis G. Lu, M.D.

D. Race, Ethnicity, and Variations in Psychiatric Diagnosis and Treatment Diane M. Herbeck, M.A.

S77. HIV Treatment Dimensions Among Diverse Ethnic and Cultural Populations APA Commission on AIDS

A. HIV-Positive Patient Panel Altha J. Stewart, M.D.

B. Cultural Considerations for Treating HIV-Infected African-American Patients Eric G. Bing, M.D.

C. Cultural Considerations for Treating HIV-Infected Latino Patients Milton L. Wainberg, M.D.

S78. Brain Substrates of Addiction: Neuroimaging as a Tool of Choice in the 21st Century

A. Using PET to Image the Neuroanatomical and Neurochemical Substrates of Cocaine Craving Anna R. Childress, Ph.D.

B. Bold fMRI Versus Spin-Tagging in Cue-Induced Cocaine Craving (4T) John M. Listerud, M.D.

C. Functional MRI During Heroin Craving in Methadone- Maintained Subjects Daniel D. Langleben, M.D.

D. fMRI of Cue-Induced Nicotine Craving Teresa R. Franklin, Ph.D.

E. Brain Substrates for Self-Control May Be Defective in Addiction John R. Monterosso, Ph.D.

S79. Optimal Strategies for Identifying and Treating Traumatized Children

A. Screening for Traumatic Exposure and PTSD Symptoms in Pediatric Settings Anthony P. Mannarino, Ph.D.

B. Cognitive-Behavioral Therapy for Traumatized Children and Their Parents Esther Deblinger, Ph.D.

C. Developmental Traumatology: Neurobiological Development in Childhood PTSD Michael D. DeBellis, M.D.

D. Pharmacological Treatments for Traumatized Children Judith A. Cohen, M.D.

E. Treating Child and Adolescent Victims of Crime: The New California Guidelines Graeme Hanson, M.D.

S80. Opiate-Substitution Treatment: International Trends and Perspectives

A. Buprenorphine: Experiences With Office-Based Substitution Treatment in Europe Marc Auriacombe, M.D.

B. Morphine Maintenance in the Treatment of Heroin Addiction Gabriele Fischer, M.D.

C. Is There a Gold Standard Medication in Opiate-Substitution Treatment? Robert G. Newman, M.D.

D. Heroin-Assisted Treatment Approaches in Europe Wim Van Den Brink, M.D.

E. Outcome Criteria and Guidelines From an International Point of View Richard N. Rosenthal, M.D.

S81. Alcohol Interventions Across the Spectrum for Community Practitioners Substance Abuse and Mental Health Services Administration

A. Underage Drinking: Changing Community Norms Robert Voas, Ph.D.

B. Identification of Fetal Alcohol Syndrome: Differentiating Developmental Disorders From Fetal Alcohol Syndrome Larry J. Burd, Ph.D.

C. Implementing Naltrexone in Alcohol Treatment in Community Settings Sherrie Gillette, M.A.

D. Multisystemic Treatment of Alcohol-Abusing Adolescents: Outcomes Scott W. Henggeler, Ph.D.

E. Implementing Motivational Enhancement Therapy Allen Zweben, D.S.W.

S82. The Schizophrenia Prodrome: Update of Research 2002

A. Intervention in the Schizophrenic Prodrome: Rationale, Studies, and Ethics Thomas H. McGlashan, M.D.

B. Diagnosis and Symptom Assessment in the Schizophrenia Prodrome Tandy J. Miller, Ph.D.

C. A Trial of Olanzapine Versus PBO in the Prodrome: Protocol and Baseline Sample Alan F. Breier, M.D.

D. Neuropsychological Status of the First-Episode Prodrome Keith A. Hawkins, Psy.D.

E. MRI and MRS Findings in Subjects With Prodromal Symptoms Diana O. Perkins, M.D.

F. Olanzapine Versus Placebo for Prodromal Symptoms Scott W. Woods, M.D.

S83. The Duty to Warn and Protect for the 21st-Century Psychiatrist

A. The Fin de Millenaire: Duty to Warn or Protect? Alan R. Felthous, M.D.

B. Judicial Responses to Tarasoff Statutes Claudia A. Kachigian, M.D.

C. Novel Approaches to TarasoffRalph Slovenko, LL.B.

D. Encroachments on Psychotherapist-Patient Privilege Robert Weinstock, M.D.

E. Risk Assessment in Tarasoff Situations Randy Borum, Psy.D.

S84. Clinical Challenges in Treating Schizophrenia

A. From First Psychotic Episode to Long-Term Outcome in Schizophrenia John L. Waddington, D.Sc.

B. PET Imaging Studies of Atypical Antipsychotics: Implications of Dosing and Mechanism of Action Shitij Kapur, M.D.

C. Managing Violent Behavior in Patients With Schizophrenia: Emerging Standards of Care Peter F. Buckley, M.D.

D. Augmentation Strategies in Treatment-Refractory Schizophrenia Robert R. Conley, M.D.

E. Management of Long-Term Side Effects of Novel Antipsychotics Prakash S. Masand, M.D.

S85. Cognitive Therapy Versus Medications for Severe Depression

A. Background and Design of a Placebo-Controlled Comparison Robert J. DeRubeis, Ph.D.

B. Response to Acute Treatment Jay D. Amsterdam, M.D.

C. Prevention of Relapse Steven D. Hollon, Ph.D.

D. Who Responds and Who Relapses? Richard C. Shelton, M.D.

S86. Reducing Aggressive Behavior: Changing the Trajectory for Drug Use Substance Abuse and Mental Health Services Administration

A. Intimate Partner Violence Among Whites, Blacks, and Hispanics Raul Caetano, M.D.

B. Modifying Aggressive Behavior via Strategic Peer Involvement Gerald August, Ph.D.

C. Cognitive-Behavioral Intervention for Aggressive Preadolescent Children (Ages 9-11) John E. Lochman, Ph.D.

D. Diagnostic-Specific Treatments for Adolescents With Substance-Use Disorders and Comorbidity Oscar G. Bukstein, M.D.

E. Family, Psychiatric, Drug Use, and Social Predictors of Violence Between Adolescence and Adulthood Ralph E. Tarter, Ph.D.

S87. New Developments in Interpersonal Psychotherapy Research

A. Maintenance Interpersonal Psychotherapy in Recurrent Depression: Appropriate for Which Patients? Ellen Frank, Ph.D.

B. Treatment Strategies for Dysthymic Disorders John C. Markowitz, M.D.

C. Interpersonal Psychotherapy Groups for Low-Income Women With PTSD Janice L. Krupnick, Ph.D.

D. Individual Interpersonal Psychotherapy for PTSD Kathryn L. Bleiberg, Ph.D.

E. Interpersonal Therapy Versus Supportive Therapy for Social Phobia Joshua D. Lipsitz, Ph.D.

S88. Treating Mental Illness and Substance Abuse in the Criminal Justice System Substance Abuse and Mental Health Services Administration

A. Family Drug Courts: Early Evaluation Findings Nancy Young

B. Pelican Bay Super Max: Treatment in Correctional Settings David Arcnambault, Ph.D.

C. Jail Diversion: Mechanisms and Services Hank Steadman

D. Successful Community Reintegration of Offenders With Mental Illness Fred C. Osher, M.D.

S89. Traumatic Response to Disaster: Neurobiology and Treatment

A. Neurobiological Mechanisms of PTSD Dennis S. Charney, M.D.

B. The Range of Human Response to Catastrophic Trauma Carol S. North, M.D.

C. Disaster Overview: Clinical Presentation National and International Perspectives David Benedek, M.D.

D. Psychopharmacotherapy of PTSD in Children and Adolescents Elizabeth B. Weller, M.D.

E. Psychopharmacology of Traumatic Response in Adults Richard Balon, M.D.

S90. Psychiatry and the Pharmaceutical Industry: Where Is the Boundary?

A. Pharmaceutical Promotion: There Is no Free Lunch Amy C. Brodkey, M.D.

B. Academia, Medical Education, and the Pharmaceutical Industry Frederick S. Sierles, M.D.

C. The Pharmaceutical Industry and Public Psychiatry Robert M. Factor, M.D.

D. Industry-Supported Medical Education: When Educators Serve Two Masters Diana M. Koziupa, M.D.

S91. The Employment Intervention Demonstration Project: Outcome of Best Practice

A. Best Practice in Employment Research: Views from the Employment Intervention Demonstration Program Coordinating Center Judith A. Cook, Ph.D.

B. The Hartford Study of Supported Employment for Severe Mental Illness: Employment and Nonvocational Outcomes Kim T. Mueser, Ph.D.

C. Effects of Fact and an Employers Consortium on Employment in Severe Mental Illness William R. McFarlane, M.D.

D. Improving Employment Outcomes for Persons With Severe Mental Illness Anthony F. Lehman, M.D.

E. Effectiveness of Long-Term Employment Support for Individuals With Severe Mental Illness Laura E. Bianhertz, Ph.D.

F. Rural-Based Supported Employment Approaches: Results From the South Carolina Site of the Employment Intervention Demonstration Project Neil Meisler, M.S.W.

G. The Texas EARNS Supported Employment Demonstration Project Marcia Toprac, Ph.D.

S92. Treatment of ADHD: From Clinical Trials to Routine Clinical Practice

A. The AACAP Stimulant Medication Practice Parameter for Treatment of ADHD Laurence L. Greenhill, M.D.

B. Treatment of ADHD: From Multimodal Treatment ADHD Trials to Routine Psychiatric Practice Peter S. Jensen, M.D.

C. Stimulant and Psychosocial Treatment of ADHD in Latino Children Glorisa Canino, Ph.D.

D. The Role of Comorbidity in the Treatment of ADHD in Routine Psychiatric Practice Farifteh F. Duffy, Ph.D.

E. Insurance Factors and ADHD Treatment in Psychiatric Practice William E. Narrow, M.D.

S93. Virtual Reality and Mental Health: State of the Art and Future Directions

A. Virtual Environments: Using a Driving Simulator to Understand Consciousness Henry J. Moller, M.D.

B. Embracing the Real World: Virtual fMRI and Virtual Reality Konstantine K. Zakzanis, Ph.D.

C. Virtual Reality Neuropsychological Assessment and Rehabilitation: Present and Future Albert A. Rizzo, Ph.D.

D. Application of Advanced Information Technologies in the Creation of Virtual Humans Norman E. Alessi, M.D.

E. Virtual Reality Therapy: A Cost-Benefit Analysis Mark D. Wiederhold, M.D.

Anchor for JumpAnchor for Jump

This beautiful stairway is one of the Pennsylvania Convention Center's design elements that help create a pleasant atmosphere for meeting goers. Its light-filled, colorful spaces prevent the cavelike feel common to other convention centers. (Photo: Top Kat)

Interactive Graphics


Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Articles